Ono Pharmaceutical Co., Ltd.
OPHLF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $487 | $503 | $447 | $361 |
| % Growth | -3.1% | 12.4% | 23.8% | – |
| Cost of Goods Sold | $148 | $127 | $110 | $94 |
| Gross Profit | $339 | $376 | $337 | $268 |
| % Margin | 69.6% | 74.7% | 75.4% | 74.1% |
| R&D Expenses | $150 | $112 | $95 | $76 |
| G&A Expenses | $126 | $73 | $69 | $63 |
| SG&A Expenses | $126 | $97 | $87 | $74 |
| Sales & Mktg Exp. | $0 | $24 | $18 | $11 |
| Other Operating Expenses | $4 | $3 | $3 | $3 |
| Operating Expenses | $279 | $212 | $185 | $153 |
| Operating Income | $60 | $163 | $152 | $115 |
| % Margin | 12.3% | 32.4% | 34.1% | 31.8% |
| Other Income/Exp. Net | -$0 | $1 | -$9 | -$10 |
| Pre-Tax Income | $59 | $164 | $144 | $105 |
| Tax Expense | $9 | $36 | $31 | $24 |
| Net Income | $50 | $128 | $113 | $81 |
| % Margin | 10.3% | 25.5% | 25.2% | 22.3% |
| EPS | 106.55 | 266.61 | 230.85 | 162.19 |
| % Growth | -60% | 15.5% | 42.3% | – |
| EPS Diluted | 106.41 | 266.6 | 230.79 | 162.16 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5 | $4 | $2 | $3 |
| Interest Expense | $5 | $0 | $1 | $1 |
| Depreciation & Amortization | $27 | $18 | $17 | $18 |
| EBITDA | $92 | $178 | $167 | $129 |
| % Margin | 18.8% | 35.5% | 37.5% | 35.6% |